Charity Dinner in Lot Vineyards Supports Cancer Research
Sabine Baldes, owner of the Clos Triguedina estate, hosted a charity dinner on June 3, 2026, at the Château de Roussillon in Saint-Pierre-Lafeuille to benefit the Toulouse Cancer Santé Foundation. The event brought together local supporters and medical representatives to fund innovative cancer research. According to foundation director general Gilles Favre, the organization focuses on medical projects that traditional institutions may not support, with a specific upcoming emphasis on pediatric leukemia research.
Building a Support Network for Cancer Research
The charity dinner served as a platform to bridge the gap between regional philanthropy and specialized medical research. Sabine Baldes, who has previously supported the foundation through donations of Prince Probus wine, organized the evening to direct proceeds toward the foundation’s work. The event was supported by the owners of the Château de Roussillon, Julien and Charlie Peignart, and members of the Disciples d’Escoffier, who contributed to the evening’s logistics and gastronomy.
Gilles Favre, director general of the Toulouse Cancer Santé Foundation, stated that the organization has operated for twenty years, working alongside clinicians at the Oncopole of Toulouse and the Rangueil hospital. The foundation relies on a network of over two hundred corporate sponsors and twenty thousand individual donors, having raised 3.5 million euros in the previous year.
Did You Know? The Toulouse Cancer Santé Foundation is a recognized public utility organization that focuses on funding innovative medical research, including recent advancements in immunotherapy and targeted therapies for lung and pancreatic cancers.
Current Research Priorities and Future Outlook
The foundation is currently prioritizing the development of new therapeutic methods for various cancers, including ORL, ovarian, and lung cancers. According to foundation officials, patients in the Occitanie region may gain access to these new targeted therapies within two to three years, following the completion of clinical trials and market authorization. The organization’s next major financial commitment involves a 1 million euro investment over the next three years to support an oncopediatric research site, which is labeled by the French National Cancer Institute (Inca).
Expert Insight: The integration of regional charitable events with established research hubs like the Oncopole suggests a strategic shift toward localized fundraising to accelerate clinical transitions. By focusing on specific projects like oncopediatrics, the foundation may be able to bypass broader institutional delays and deliver specialized care to patients more efficiently.
Frequently Asked Questions
What is the primary goal of the Toulouse Cancer Santé Foundation?
The foundation aims to fund innovative medical research and support clinician-researchers in developing new therapeutic methods for various cancers, including pediatric leukemia, lung, and pancreatic cancers.
Who supports the foundation’s financial needs?
The foundation is supported by a network of more than two hundred corporate sponsors and approximately twenty thousand individual donors.
What is the next major project for the foundation?
The foundation plans to fund an oncopediatric research site—labeled by the Institut national du cancer (Inca)—with a 1 million euro investment over the next three years to fight childhood leukemia.
How might the increased focus on regional fundraising impact the speed at which new cancer therapies reach patients in the Occitanie region?